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Introduction: Use of synthetic cannabinoids (SC) has recently emerged as a new drug epidemic. Our 
emergency departments (EDs) received a surge of SC users presenting with lethargy and bradycardia, 
contrasting prior reports of SC-induced tachycardia and agitation.Our goal was to describe these novel 
presentations and characterize the compounds.
Methods: We present a case series of patients with SC intoxication who presented to our toxicology service 
covering two tertiary care EDs between 2/11/2015 and 6/23/2015. A retrospective chart review recorded initial 
vital signs, chief complaint and clinical course. Urine, blood and xenobiotic samples were analyzed using 
either liquid chromatography/mass spectrometry or gas chromatography/mass spectrometry. We compared 
resulting spectra against databases containing numerous SCs or metabolites and scored based on a 
reference comparison. 
Results: Between 2/11/2015 and 6/23/2015, we identified 141 visits. Males comprised 139 visits (age 
range 21-68 years; median 35, interquartile range 20). Sixty-eight percent presented with lethargy or loss of 
consciousness. Hypotension (SBP <90 mmHg) and bradycardia (HR<60 bpm) were seen in 10% and 24% 
of visits, respectively. While most patients were discharged after observation, three were admitted to the 
intensive care unit and seven to telemetry. Admissions were for vital sign instability, bradycardia requiring 
pacing, prolonged sedation and respiratory failure requiring mechanical ventilation.
Laboratory analysis revealed SC in the XLR-11 family in 18/36 drug, 9/12 blood, and 23/31 urine samples. 
Carboxamide indazole derivative (CID) family compounds were detected in 13/36 drug samples, 21/31 urine 
samples, but no blood samples; 11/31 drug samples contained both XLR-11 and CID. Other compounds 
detected included PB-22 and nicotine. No JWH compounds, opiates, imidazoline receptor agonists, 
benzodiazepines or other sedative-hypnotics were detected.
Conclusion: Unlike their predecessors, novel SC may be associated with significant central nervous system 
depression and bradycardia. While prior reports indicated that SC mostly contained JWH compounds, none 
were detected in these samples. The most commonly identified compounds in this series were CID and alkyl 
SC derivatives, such as INACA compounds and XLR-11. These tend to be full agonists at the cannabinoid 
receptor and are presumably more potent. The lack of other depressants suggests that the clinical findings are 
due to the combination of these compounds and not coingestants or adulterants. SC intoxication should be 
considered for patients with undifferentiated psychomotor depression and bradycardia. [West J Emerg Med. 
2018;19(3)567-572.]
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Population Health Research Capsule
What do we already know about this issue? 
Synthetic cannabinoid intoxication has 
emerged as an epidemic, and can present 
with a wide array of gastrointestinal, 
neuropsychiatric and cardiovascular 
symptoms. 
 
What was the research question?  
Are bradycardia and central nervous 
system (CNS) depression associated 
with novel synthetic cannabinoids, or 
coingestants or adulterants?
 
What was the major finding of the study? 
Novel synthetic cannabinoids were detected 
with no coingestants and are associated 
with CNS depression and bradycardia.
 
How does this improve population health?  
Synthetic cannabinoid intoxication should be 
considered for patients with undifferentiated 
CNS depression and bradycardia.
INTRODUCTION
Synthetic cannabinoids (SC) are a class of drugs that are 
becoming increasingly popular throughout the United States 
and Europe. Also known as “K2,” “spice,” spike,” or “legal 
marijuana,” SC are causing intoxication requiring emergency 
department (ED) visits in epidemic and unparalleled numbers.1 
Patients present with a wide array of symptoms, ranging from 
nausea and vomiting to confusion, agitation, short-term memory 
loss, cognitive impairment, psychosis, seizures, arrhythmias, 
strokes and even death.2 SC have often been associated with 
sympathomimetic effects such as mydriasis, hypertension and 
tachycardia.2 We present a case series of patients with SC 
intoxication who presented atypically with central nervous 
system (CNS) and cardiovascular depression over a five-month 
period; in addition, we present an analysis of blood, urine and 
SC samples using mass spectrometry. Intoxication with SC 
products should be considered for patients with undifferentiated 
psychomotor depression and bradycardia in addition to the 
excitatory effects previously described.
BACKGROUND
In early 2015 our suburban, tertiary care EDs experienced a 
large influx of patients presenting with lethargy and 
psychomotor depression, often requiring admission to the 
telemetry or intensive care units and rarely requiring intubation. 
The patients usually experienced sudden and complete 
resolution of symptoms after several hours in an obtunded state. 
Large cohorts of these patients simultaneously presented from a 
nearby psychiatric center that provided inpatient, outpatient and 
residential services. The increased volume of intoxications 
exacerbated ED crowding. Patients later admitted to SC use, 
and some produced samples of the plant material. Questions 
arose regarding the potential contamination of these substances 
with other agents, such as clonidine or digoxin, or whether these 
presentations were due to newer generation SC.
We selected cases for this series from the toxicology consult 
service database for patients suspected of SC use. Blood and 
urine samples were collected from the patients when possible. 
The unknown drug samples were analyzed and compared to a 
reference database to identify the compounds present.
MATERIALS AND METHODS
We included two tertiary care EDs in our case series. In 
total, 141 ED visits were selected by toxicologists from the 
consult service database based on abnormal triage vitals, 
history of SC use or an obtunded mental state upon 
presentation. Twelve blood and 31 urine samples were 
collected. The 36 samples of plant material provided by 
patients were collected and analyzed using liquid 
chromatography/mass spectrometry and gas chromatography/
mass spectrometry (GC/MS). The samples were not correlated 
with specific patients. This retrospective chart review was 
approved by an institutional review board.
 Standards and Reagents
We purchased chemical reagents, including ethyl acetate, 
methanol, water, and formic acid from VWR International 
(Bridgeport, NJ). All solvents were high performance liquid 
chromatography grade or better.
 
Sample Preparation
Samples were extracted with organic solvent and 
concentrated to isolate any drugs present on the plant material. 
Briefly, 5 mg aliquots of an unknown plant material, or 100 μL 
of submitted blood/urine, were transferred to screwtop 
centrifuge tubes. Two mL of ethyl acetate were added and the 
samples were thoroughly mixed. Samples were extracted for 
10 minutes on a nutating mixer at 24 revolutions per minute. 
The solvent was transferred to clean test tubes and the extracts 
were evaporated to dryness under nitrogen at 45°C. Samples 
were reconstituted in 50 μL methanol and 50 μL 0.1% formic 
acid in water and transferred to conical autosampler vials for 
analysis by liquid chromatography time-of-flight (TOF) mass 
spectrometry.  Similarly, samples were reconstituted in 50 μL 
ethyl acetate for GC/MS confirmation analysis.  Biological 
samples underwent a 20-minute room temperature hydrolysis 
period prior to liquid-liquid extraction. 
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Liquid Chromatography Conditions
We used an Agilent Technologies 1290 liquid 
chromatograph (LC) equipped with a Zorbax Eclipse Plus 
C-18 column (2.1mm x 50mm x 1.8μm) for chromatographic 
separation of the unknown plant material extract. The LC 
columns were maintained at 50°C in the thermostated column 
compartment. Mobile phases consisted of 0.1% formic acid in 
deionized water (A) and 100% methanol (B). The mobile 
phase flow rate was set at 0.7 mL/min. Initial mobile phase 
conditions were held at 0%B for 0.5 minutes then increased to 
95%B over five minutes. Mobile phase conditions returned to 
initial starting conditions for a final run time of six minutes.
 
Time-of-Flight Mass Spectrometry Conditions
We operated an Agilent Technologies 6230 TOF mass 
spectrometer with a Jetstream electrospray source in positive ion 
mode with the following common parameters: nitrogen drying 
gas temperature 350°C; nitrogen sheath gas temperature 400°C; 
nitrogen drying gas flow 10 L/min; nitrogen sheath gas flow 11 L/
min; nebulizer pressure 45 psi; capillary voltage 4000 V; and 
nozzle voltage 1000 V. Accurate mass spectra were acquired at a 
rate of 1 spectra per second over the range of 100 – 1700 m/z. 
 
TOF Data Analysis
We compared all acquired spectra against the Agilent 
Technologies Forensic Toxicology PCD Accurate Mass 
Database of over 7,500 compounds. All spectra were scored 
based on deviation from expected exact mass assignment 
(ΔPPM), chromatographic retention time, and peak abundance. 
Scores greater than 90% match were considered positive. 
Where available, unknown compounds were confirmed as 
positive by comparison to a known reference material.
 
Gas Chromatography Mass Spectrometry Conditions
We used an Agilent Technologies 7980A series gas 
chromatograph equipped with an HP-5MS column (30m x 
0.25mm x 0.25μm), a 5975C series mass selective detector and 
a 7693 series autoinjector module for chromatographic 
separation of the unknown plant material extract.  The transfer 
line temperature was 295°C.  The oven program consisted of an 
equilibration time of 0.5 minutes, initial temperature of 100°C, 
ramp of 15°C/minute to a final temperature of 325°C. The total 
run time was 20 minutes. The inlet mode was splitless with a 
temperature of 265°C and an injection volume of 1μL.
 
GC/MS Data Analysis
We compared all acquired spectra against the Scientific 
Working Group for the Analysis of Seized Drugs 
(SWGDRUG) database. All spectra were scored based on the 
search quality of the generated spectrum in comparison to the 
reference spectrum. We considered search quality scores 
greater than or equal to 90% positively detected based on 
chromatographic retention time, and peak abundance. Where 
available, unknown compounds were confirmed as positive by 
comparison to a known reference material.
 
RESULTS
We identified 141 patient visits from 2/11/2015 to 
6/23/2015 (Table 1). Of these patients, 139 (98%) were male 
with a median age of 35 (range 21-68 years old). Ninety-seven 
(68%) of the patients presented with lethargy or an altered 
level of consciousness. A smaller proportion presented with 
hypotension (systolic blood pressure < 90 mmHg) (10%) or 
bradycardia (heart rate < 60 bpm) (24%).
We analyzed 36 drug samples (Table 2) and found that the 
majority of them contained carboxamide indazole derivatives 
(CID) or XLR-11, an alkyl derivative. Eleven of the samples 
had both derivative classes detected in the mixture and 14 had 
no SC identified.
We found that 24 of 31 urine samples tested positive for a 
SC; 74% of urine samples contained XLR-11, and 35% contained 
carboxamide indazole derivatives (CID). Nine of the 12 blood 
samples (75%) contained suspected metabolite of XLR-11. None 
of the blood samples tested positive for CID. There were no JWH 
compounds, opioids, imidazoline receptor agonist or sedative-
hypnotics detected in any of the material, urine or blood samples. 
DISCUSSION
Hundreds of distinct SC compounds have been identified.2 
SCs are responsible for a rapidly growing number of 
presentations to EDs throughout the U.S. in the past several 
years.1 SC use causes intense highs and has become popularized 
due to accessibility, affordability and limited detectability in 
common drug screens.3 Intoxications often present in clusters due 
to local distribution of a single product and great variability in the 
herbal mixtures. One study found a range of 2.3-22.9 mg/g of 
cannabimimetics in the herbal mixtures.4 In addition, SC have 
been found to be more potent than Δ9-THC;2 the SC 5F-ADB-
PINACA, a CID compound similar to a SC detected in our study, 
is over 1,000 times more potent than Δ9-THC.5
In March 2011 the U.S. Department of Justice categorized 
Total number %
Total visits 141 100
Male visits 139 98
Lethargy/LOC 97 68
Hypotension (<90 SBP) 14 10
Bradycardia (<60 HR) 34 24
ICU admissions 4 3
Telemetry admissions 10 7
Table 1. Patients presenting with symptoms of synthetic 
cannabinoid intoxication.
LOC, loss of consciousness; ICU, intensive care unit.
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the five most commonly abused SCs (JWH-018, JWH-073, 
JWH-200, CP-47,497 and its C8 homolog) as Schedule I 
drugs under 21 U.S.C.811(h) of the Controlled Substances 
Act.6,7,8 As local outbreaks continued, the novel compounds 
(detected in this study) were identified and added to the 
Controlled Substances Act.
ED visits increased from 11,406 in 2010 to 28,531 in 
2011.9,10 Visits from patients 12-17 years old more than 
doubled from 3,780 to 7,584, while visits from patients18-20 
years old increased from 1,881 to 8,212.9,10 In 2011, SCs were 
the second most commonly used drug in the 10th grade and the 
third most common in eighth grade following marijuana and 
inhalants.2,11 Despite the federal ban on SCs that year, there 
was no decline in frequency of use in high school students the 
following year. However, use declined in each of the next 
three years.11 Users of SCs vary greatly in both demographics 
and motivation, but are typically males aged 13-59, most with 
polydrug use and are found in larger, urban populations.2,12
SCs are known to interact with the cannabinoid receptors, 
CB1 and CB2, leading to changes in levels of multiple 
neurotransmitters including acetylcholine, dopamine, 
noradrenaline, glutamine and GABA.2 Genetic polymorphisms in 
enzymes responsible for metabolism of SCs can lead to increased 
blood levels of the parent compound and prolonged duration of 
action, and therefore a potential increased risk of adverse 
events.10,13 In addition, many SC metabolites retain biological 
activity.10,13 Combination of these metabolites with accumulation 
of the parent drug creates complex pharmacodynamics, especially 
when the multitude of other compounds typically found within 
herbal mixtures is considered.
SCs have been reported to exhibit a wide array of effects. 
CNS effects include psychosis, anxiety, agitation, irritability, 
memory changes, sedation, confusion and hallucinations,14 in 
addition to lowering the seizure threshold in susceptible 
individuals.15 Reported cardiovascular effects include 
tachycardia, chest pain, dysrhythmias, myocardial ischemia13 
and cerebrovascular accident caused by embolisms due to 
cardiac arrhythmias or reversible cerebral vasoconstriction 
syndrome.16,17 In an analysis of a Centers for Disease Control 
and Prevention report of 3,573 calls to poison control for 
SC-related adverse events, the most common effects were 
agitation (35%), tachycardia (29%), drowsiness or lethargy 
(26%), vomiting (16%), and confusion (4%).1
Sample (total) Any SC (%) XLR-11 (%) CID (%) XLR-11 and CID (%) Nicotine (%) No SC definitively identified (%)
Drug (36) 22 (61) 18 (50) 13 (36) 11 (31) 5 (14) 14 (39)
Blood (12) 9 (75) 9* (75) Not detected Not detected Not detected 3 (25)
Urine (31) 24 (77) 23* (74) 21 (68) 20 (65) Not detected 7 (23)
Table 2. Analyses of samples for presence of synthetic cannabinoids.
CID, carboxamide indazole derivatives, SC, synthetic cannabinoids.
*Suspected metabolite of XLR-11 (UR-144 compounds).
In early 2010, JWH-018 was detected in 100% of SC 
products. However, as legislation regarding SCs changed in 
2010 and 2011, the incidence of JWH-018 decreased, while 
similar yet compositionally distinct compounds appeared. By 
the end of 2012, JWH-018 was not detected in samples, and 
XLR-11 became the most common SC detected,18 as exhibited 
in our sample analysis.
In our case series, CID and alkyl SC derivatives, such as 
INACA compounds and XLR-11,19 were the most commonly 
detected with no opiates, imidazoline receptor agonists, 
benzodiazepines or other sedative-hypnotics detected that 
might explain the atypical presentations. Sixty-one percent of 
the confiscated products contained a SC and 31% contained 
both XLR-11 and CID. Seventy-five percent of blood samples 
and 77% of urine samples tested positive for SC. Unlike their 
predecessors, novel SC appear to be associated with 
significant CNS depression and bradycardia. The compounds 
detected in our case series tended to be full agonists at the 
cannabinoid receptor and are more potent than Δ9-THC.20 The 
lack of other CNS and cardiovascular depressants suggests 
that the clinical findings are due to the combination of these 
compounds and not coingestants or adulterants.
It is important to note that many substances detected in the 
plant samples were not detected in the blood or urine samples. 
Some examples include 5-Fluoro-NNEI 2’-naphthyl isomer, 
5-fluoropentylindole, NM-2201 and NPB-22. There are multiple 
explanations for these findings. The patient may have used SC 
products that were not included in our plant samples and 
therefore would not be associated with the urine and blood 
samples. It is also possible that the metabolites of the compound 
were not in the database or that the level was below the LC TOF 
detection limits. Furthermore, the metabolite may have been 
metabolized to a common XLR metabolite that was detected, or 
the drug had already been eliminated from the body. 
LIMITATIONS
Our case series demonstrates some of the severe effects 
these novel compounds can cause. However, the study has a 
number of important limitations. First, the selection of patients 
was based on the judgment of our ED team and toxicologists 
based on abnormal vital signs, subjective history from the 
patient, presentation of decreased mental status and clinical 
judgment. Many intoxicated patients may have been evaluated 
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and treated without being included in the study. In addition, 
patients may have had altered mental status for reasons other 
than SC intoxication and may have been erroneously included 
in the study because their ED arrival was associated with other 
patients with SC intoxication. Although there were 141 visits, 
several patients with recurrent intoxications were included as 
multiple visits in the study. 
The SC samples were provided by patients, but it should 
not be assumed that the specific sample was necessarily the 
cause of their intoxication. Furthermore, the samples were 
collected anonymously, without designation to a specific 
patient, and therefore we were unable to identify which of the 
patients presenting with bradycardia tested positive for certain 
compounds. This significantly diminished our ability to 
conclude that certain types of SC are associated with more 
profound presentations of bradycardia and psychomotor 
depression. Lastly, the majority of the patients presented from 
a large, nearby psychiatric center. The patients often presented 
as groups, possibly due to simultaneous drug use with the 
same sample. This patient population tends to have multiple 
comorbidities, and members may be taking neuroleptic 
medications that may increase the opportunity for interactions 
with the cannabinoids. This is a population with an increased 
risk of substance use, and therefore the results of our case 
series cannot necessarily be extrapolated to other populations.
CONCLUSION
SC products are inexpensive, easily obtained, avoid 
common drug detection screens and cause a wide array of signs 
and symptoms. The changing composition of available SCs 
corresponds to the variability exhibited in patient presentations. 
SC intoxication should be considered for patients with varied 
clinical effects, including undifferentiated psychomotor 
depression, loss of consciousness, hypotension and bradycardia.
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